GlassScriptPhysician profile
Malak A Awad
NPI 1730533985
$1,126.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $219 · 2021: $53.12 · 2022: $273 · 2023: $286 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.13 | 2021-2024 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $189.68 | 2020-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $150.21 | 2020-2022 | |
| Amgen INC. | $80.43 | 2019-2024 | Krystexxa |
| Lilly USA, LLC | $63.47 | 2019-2022 | |
| Glaxosmithkline, LLC. | $62.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.00 | 2024 | Ofev |
| Biosense Webster, INC. | $26.96 | 2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $21.82 | 2019 | |
| Genzyme Corporation | $19.57 | 2020 | |
| Travere Therapeutics, INC. | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malak Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.